November 14, 2023
2 min watch
Save
VIDEO: Tarsus discusses Xdemvy educational efforts, distribution plan
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Aziz Mottiwala of Tarsus Pharmaceuticals discusses Xdemvy for the treatment of Demodex blepharitis.
Mottiwala overviews the educational efforts and distribution approach for Xdemvy (lotilaner ophthalmic solution 0.25%).
“You can think about our educational efforts in terms of increasing diagnosis and then sending the value of treatment for those patients,” he said.
Xdemvy is the first product approved for the treatment of Demodex blepharitis.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mottiwala reports being the chief commercial officer of Tarsus Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.